Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $36.4 million.

  • Tonix Pharmaceuticals Holding's Operating Expenses rose 9785.05% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year decrease of 2790.15%. This contributed to the annual value of $146.8 million for FY2024, which is 1636.73% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Operating Expenses is $36.4 million, which was up 9785.05% from $30.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Operating Expenses registered a high of $79.5 million during Q2 2024, and its lowest value of $18.4 million during Q3 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Operating Expenses averaged around $32.8 million, with its median value being $30.3 million (2025).
  • Over the last 5 years, Tonix Pharmaceuticals Holding's Operating Expenses had its largest YoY gain of 9785.05% in 2025, and its largest YoY loss of 6190.58% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Operating Expenses (Quarter) stood at $31.1 million in 2023, then decreased by 19.44% to $25.1 million in 2024, then skyrocketed by 45.07% to $36.4 million in 2025.
  • Its Operating Expenses stands at $36.4 million for Q3 2025, versus $30.3 million for Q2 2025 and $18.5 million for Q1 2025.